Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
A follistatin-based protein "trap": it intercepts myostatin and activins right inside the muscle it is injected into and releases their brake on growth. It acts locally, not body-wide.
Size: 1 mg
No published analyses yet.
Research, properties and limitations
AI can make mistakes
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Starting cohort (IM, every 3 weeks) | 150 mg per muscle | Starting dose |
| Escalation (IM, every 3 weeks) | 200 mg per muscle | Increase if needed |
| Main regimen (IM, every 3 weeks) | 240 mg per muscle | Maximum in this schedule |
Research overview · reference
Below is a short summary of what the authors of published studies reported. It is not medical advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Local reactions at the injection site | Adults with facioscapulohumeral muscular dystrophy, local intramuscular administration | Described without a frequency; the publication gives no complete frequency tables | [1] |
| Myalgia | The same participants | Described without a frequency | [1] |
| Swelling | The same participants | Described without a frequency | [1] |
FAQ
Find answers to questions about ACE-083 and related materials.
ACE-083 is neither a peptide nor an antibody, but a fusion protein "trap" developed by Acceleron Pharma: a domain of human follistatin joined to the Fc fragment of an immunoglobulin. The trap works simply: it floats around muscle cells and intercepts signalling proteins — myostatin, activin A, activin B and GDF11 — before they can reach their receptors and press the "growth brake".
Source / documentationIts defining feature is locality: ACE-083 was designed to act only in the muscle it is injected into, not systemically across the body. By comparison, bimagrumab blocks the activin receptor itself and acts systemically, while ACE-083 intercepts the ligands locally.
Source / documentationIn phase 2 studies it was given intramuscularly directly into the target muscle (the starting cohort used 150 mg every 3 weeks), with dosing tied to the specific muscle rather than body weight. Study regimens are in the dosing guide on this page.
Source / documentationNo — by design the effect is local: the muscle that grows is the one it was injected into. That is the fundamental difference from systemic blockers of the myostatin/activin pathway. What the studies showed is honestly reviewed in the ACE-083 monograph in our wiki.
Source / documentationThere is no complete safety profile for use outside studies, so an honest exhaustive list cannot be compiled. A full review of the known data is in the ACE-083 monograph in our wiki.
Source / documentationKeep the dry powder in a dry, dark place at a low temperature; once dissolved, store it in the refrigerator and do not freeze it again. Details are in the ACE-083 guide on this page.
Source / documentationYou can buy ACE-083 right on this page of our store: current prices and stock are shown in the product card. We deliver across Ukraine with Nova Poshta — to a branch, a parcel locker, or by courier. Payment is by card, by crypto (with a 5% discount), or on delivery. The product ships with the certificate of analysis (COA) for its exact batch.
Source / documentationShare your experience
No reviews yet. Tell others what you think of this product.
ACE-083 is neither a peptide nor an antibody, but a fusion protein "trap" developed by Acceleron Pharma: a domain of human follistatin joined to the Fc fragment of an immunoglobulin. The trap works simply: it floats around muscle cells and intercepts signalling proteins — myostatin, activin A, activin B and GDF11 — before they can reach their receptors and press the "growth brake".
Its defining feature is locality: ACE-083 was designed to act only in the muscle it is injected into, not systemically across the body. In phase 2 studies it was given intramuscularly directly into the target muscle (the starting cohort used 150 mg every 3 weeks), with dosing tied to the specific muscle rather than body weight. Details are in the ACE-083 monograph.
How it differs from bimagrumab: that one blocks the activin receptor itself and acts systemically, while ACE-083 intercepts the ligands locally. Study regimens are in the dosing guide; the full line is in the myostatin/activin category.
Every batch is purity-tested by HPLC, and the certificate of analysis (COA) for your exact batch is in our COA archive. Keep the dry powder in a dry, dark place at a low temperature, and the dissolved solution in the refrigerator.